Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Ohkuma Y, Hayashi T, Sakai T, Watanabe A, Tsuneoka H.

Graefes Arch Clin Exp Ophthalmol. 2013 Aug;251(8):1909-17. doi: 10.1007/s00417-013-2289-4. Epub 2013 Mar 2.

PMID:
23456099
2.

Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.

Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.

Ophthalmology. 2014 Feb;121(2):558-65. doi: 10.1016/j.ophtha.2013.09.024. Epub 2013 Nov 20.

PMID:
24268858
3.

Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.

Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregório T, Cachulo ML, Pires IA, Cunha-Vaz JG, Murta JN.

Retina. 2013 Feb;33(2):309-15. doi: 10.1097/IAE.0b013e3182670fbe.

PMID:
23095766
4.

Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.

Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S.

Retina. 2013 Feb;33(2):316-23. doi: 10.1097/IAE.0b013e318280769c.

PMID:
23314238
5.
6.

Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F.

Am J Ophthalmol. 2014 May;157(5):1033-7. doi: 10.1016/j.ajo.2014.01.022. Epub 2014 Jan 30.

PMID:
24487046
7.

Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M.

Int Ophthalmol. 2017 Jun;37(3):483-489. doi: 10.1007/s10792-016-0286-4. Epub 2016 Jul 8.

PMID:
27392913
8.

Half-fluence photodynamic therapy in acute central serous chorioretinopathy.

Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S.

Retina. 2012 Nov-Dec;32(10):2014-9. doi: 10.1097/IAE.0b013e318242b9ab.

PMID:
22466482
9.

Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R.

Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1697-705. doi: 10.1007/s00417-013-2270-2. Epub 2013 Feb 7.

PMID:
23389551
10.

Photodynamic therapy for chronic central serous chorioretinopathy.

Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F.

Acta Ophthalmol. 2010 May;88(3):371-6. doi: 10.1111/j.1755-3768.2008.01408.x. Epub 2009 Nov 27.

11.

Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.

Kim YK, Ryoo NK, Woo SJ, Park KH.

Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2063-73. doi: 10.1007/s00417-014-2926-6. Epub 2015 Jan 24.

PMID:
25616728
12.

Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.

Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF; Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee.

Ophthalmology. 2014 May;121(5):1073-8. doi: 10.1016/j.ophtha.2013.11.040. Epub 2014 Jan 16.

PMID:
24439758
13.

[Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].

Liu Y, Li L, Xu G, Wang W.

Zhonghua Yan Ke Za Zhi. 2016 May;52(5):328-34. doi: 10.3760/cma.j.issn.0412-4081.2016.05.004. Chinese.

PMID:
27220704
14.
15.

Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.

Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O.

Am J Ophthalmol. 2011 Feb;151(2):303-9.e1. doi: 10.1016/j.ajo.2010.08.019. Epub 2010 Dec 18.

PMID:
21168824
16.

Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.

Fujita K, Shinoda K, Imamura Y, Matsumoto CS, Mizutani Y, Mizota A, Yuzawa M.

Am J Ophthalmol. 2012 Sep;154(3):579-85. doi: 10.1016/j.ajo.2012.03.043. Epub 2012 Jul 20.

PMID:
22818904
17.

Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.

Kim YK, Ryoo NK, Woo SJ, Park KH.

Am J Ophthalmol. 2015 Jul;160(1):72-84.e1. doi: 10.1016/j.ajo.2015.04.011. Epub 2015 Apr 14.

PMID:
25887629
18.

Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy.

Copete S, Ruiz-Moreno JM, Cava C, Montero JA.

Graefes Arch Clin Exp Ophthalmol. 2012 Jun;250(6):803-8. doi: 10.1007/s00417-011-1900-9. Epub 2012 Jan 6.

PMID:
22222922
19.

Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.

Tseng CC, Chen SN.

Br J Ophthalmol. 2015 Aug;99(8):1070-7. doi: 10.1136/bjophthalmol-2014-305353. Epub 2015 Feb 13.

PMID:
25680621
20.

One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.

Ophthalmology. 2015 Mar;122(3):555-61. doi: 10.1016/j.ophtha.2014.09.034. Epub 2014 Nov 18.

PMID:
25444637

Supplemental Content

Support Center